Press Releases | Medtronic

Month Year

Email alerts

May 1, 2018

Medtronic Receives FDA Approval for Deep Brain Stimulation Therapy for Medically Refractory Epilepsy

7-Year Data from the SANTE Trial Showed Median Seizure Frequency Reduction of 75 percent in Patients with Drug-Resistant Epilepsy with Partial-Onset Seizures Receiving DBS Therapy.

DUBLIN - May 1, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval for Medtronic'
May 1, 2018

Medtronic Announces TiONIC(TM) Technology, a Titanium 3D Printed Platform for Spine Surgery Implants

Technology Allows for Creation of More Intricate Implant Designs and Surface Textures

DUBLIN and NEW ORLEANS - May 1, 2018 - Medtronic plc (NYSE: MDT) today announced the launch of a titanium 3D printed platform - TiONIC(TM) Technology - that enables more complex designs and...
Apr 30, 2018

Medtronic Announces FDA Approval of Infuse(TM) Bone Graft in New Spine Surgery Indications Using PEEK Interbody Implants

Approval Adds Two Additional Implants to Current Spine Labeling

DUBLIN - April 30, 2018 - Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of Infuse(TM) Bone Graft in new spine surgery indications. InfuseBone Graft is...
Apr 17, 2018

Medtronic Expands Focus on Interventional Oncology with Its U.S. Launch of OptiSphere(TM) Embolization Spheres

Product Line Offers Unique, Resorbable Option for Patients with Hypervascular Tumors

DUBLIN - April 17, 2018 - Medtronic plc (NYSE: MDT) today announced its U.S. launch of OptiSphere(TM) embolization spheres, a resorbable embolic platform designed for embolization of hypervascular...
Apr 10, 2018

Medtronic Expands Visualase(TM) MRI-Guided Laser Ablation System to European Markets with CE Mark Approval

DUBLIN - April 10, 2018 - Medtronic plc (NYSE: MDT) announced today the CE (Conformité Européenne) Mark and European launch of the Visualase(TM) MRI-Guided Laser Ablation System. The Visualase...
Jan 16, 2018

Medtronic Receives FDA Clearance for Riptide(TM) Aspiration System

New System Expands Neurovascular Product Portfolio for the Treatment of Acute Ischemic Stroke

DUBLIN - January 16, 2018 - Medtronic plc (NYSE:MDT) today announced that the company's Neurovascular business unit received U.S. Food and Drug Administration (FDA) clearance of the Riptide(TM)...
Jan 11, 2018

New Study Shows Superiority of Intrathecal Baclofen Therapy (ITB Therapy(SM)) Over Oral Medication for the Treatment of Severe Post-Stroke Spasticity

Therapy Delivered via the Medtronic SynchroMed(TM) II Infusion System

DUBLIN - January 11, 2018 - Medtronic plc (NYSE:MDT) today announced the publication of results from the 'Spasticity In Stroke-Randomised Study' (SISTERS) trial in the Journal of Neurology,...
Jan 10, 2018

FDA Approves Innovative Clinician Programmer for the Medtronic SynchroMed II Intrathecal Drug Delivery System for Chronic Pain and Severe Spasticity

SynchroMed(TM) II for Chronic Pain Is an Alternative to Systemic Opioids for Many Patients

DUBLIN - January 10, 2018 - Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of a new clinician programmer for use with the SynchroMed(TM)II Intrathecal...
Jan 9, 2018

Medtronic Enrolls First Patient In Pain Study to Assess Optimized Spinal Cord Stimulation Programming

As More Physicians Seek Non-Opioid Treatment Options, the Vectors Study Will Further Advance Understanding of New Approaches to Optimal Spinal Cord Stimulation Treatment

DUBLIN - January 9, 2018 - Medtronic plc (NYSE:MDT) today announced the first patient enrolled in the Vectors Post Market Clinical Study. The study will follow patients with chronic intractable...

Show per page